News for Antigenics, Inc. (ANTI)

US FDA Approves Expanded Age Indication for GSK's AREXVY, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk

Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes1 Clinical development programme continues to...

GREENWICH, Conn., April 15, 2024 (GLOBE NEWSWIRE) -- Regeneron Ventures announces its formation as a venture capital fund focused on promising...

GSK's respiratory syncytial virus (RSV) vaccine, Arexvy, is under priority review by the FDA for a label expansion to age group 50-59. Read more here.

Arexvy's approval will help protect adults 60 years of age and older in Japan from RSV disease for the first time, including those living with underlying medical conditions who are...

GSK Shares Positive Data for AREXVY

The Food and Drug Administration ((FDA)) on Wednesday approved Arexvy from GSK (GSK) making it the first U.S.-cleared shot for respiratory syncytial virus. Read more here.

GSK plc today announced that the US Food and Drug Administration Vaccines and Related Biological Products Advisory Committee voted that the available data support the safety and... | March 1, 2023

Read Analyzing Agenus (NASDAQ:AGEN) and PharmaCyte Biotech (OTCMKTS:PMCB) at ETF Daily News